Honokiol Crosses BBB and BCSFB, and Inhibits Brain Tumor Growth
Author Information
Author(s): Wang Xianhuo, Duan Xingmei, Yang Guangli, Zhang Xiaoyan, Deng Linyu, Zheng Hao, Deng Chongyang, Wen Jiaolin, Wang Ning, Peng Cheng, Zhao Xia, Wei Yuquan, Chen Lijuan
Primary Institution: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China
Hypothesis
Honokiol could cross the BBB and BCSFB for the treatment of gliosarcoma.
Conclusion
Honokiol effectively crosses the BBB and BCSFB and inhibits brain tumor growth in both rat and human glioma models.
Supporting Evidence
- Honokiol showed a significant reduction in tumor volume in both rat and human glioma models.
- Honokiol crossed the BBB and BCSFB effectively, with brain/plasma concentration ratios indicating good penetration.
- In vitro studies demonstrated dose-dependent inhibition of gliosarcoma cell growth.
- Treatment with honokiol improved survival rates in both animal models.
Takeaway
Honokiol is a natural compound that can get into the brain and help stop brain tumors from growing.
Methodology
The study involved evaluating honokiol's ability to cross the BBB and BCSFB, assessing its effects on gliosarcoma cells in vitro, and using rat and human glioma models to test its anti-tumor activity.
Participant Demographics
Male Sprague-Dawley rats and male Fisher 344 rats were used in the study.
Statistical Information
P-Value
0.000
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website